Starmer’s controversial US pharma deal could cost NHS billions and increase mortality

Keir Starmer's recent agreement with the US on pharmaceutical imports has raised concerns about its potential costs to the NHS and public health. As outlined in a report published this week, the deal, struck in December with then-President Donald Trump, could lead to an additional £44.7 billion in spending, ultimately affecting patient care and safety.

Impact of the Pharma Deal on NHS Funding

The agreement entails a significant shift in NHS funding, with the government expected to double its spending on branded drugs over the next decade, from 0.3% to 0.6% of national income. This increase comes at the expense of essential services, including cancer scans and staffing for doctors and nurses.

• £1 billion annual cost initially promised by the government
• Projected total cost by 2036: £44.7 billion
• Potential increase in avoidable deaths: 229,000

Critics argue that this deal represents a betrayal of public trust, with promises made by Health Secretary Wes Streeting now appearing to be false. Streeting had assured the public that the NHS would not be compromised, yet the reality indicates a different story.

Democratic Scrutiny Lacking in Pharma Agreement

Despite the deal's implications, parliamentary oversight has been minimal. MPs were only allowed to discuss the changes long after the agreement was enacted, leading to accusations of democratic failure. The use of statutory instruments to introduce the deal without thorough debate has been criticized as a tactic to avoid scrutiny.

As noted by Labour backbencher Rachael Maskell, the delay in parliamentary debate means that “everything [the junior minister] is saying is in the press release.” This has raised alarms over transparency and accountability within the government.

Healthcare Consequences of Increased Drug Spending

The British Medical Journal's analysis highlights the severe repercussions of the deal on public health. The anticipated shift in funding will result in fewer resources for critical healthcare services, which could lead to an increase in mortality rates. The authors of the study describe the projected deaths as a “conservative” estimate, indicating that the actual impact could be even more dire.

With the NHS facing budget constraints, the shift towards higher spending on pharmaceuticals will likely mean less funding for essential medical services. The report underscores the urgent need for a reassessment of the agreement and its long-term implications for public health.